---
schema_version: "secwatch.filing_event.v1"
accession: "0001789769-24-000057"
form_type: "8-K"
ticker: "TIL"
cik: "0001789769"
company_name: "Instil Bio, Inc."
filed_at: "2024-05-10T23:59:59+00:00"
generated_at: "2026-06-02T04:02:32.417071+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Instil Bio reports Q1 net loss $3.74/share; cash runway beyond 2026

## Summary
- Cash, equivalents and investments of $161.5M at March 31, 2024; runway extends beyond 2026.
- Net loss per share (GAAP) $3.74 vs $8.77 YoY; non-GAAP loss per share $2.39 vs $4.29.
- R&D expenses fell to $7.3M from $20.7M; restructuring/impairment charges dropped to $4.3M.
- Preparing potential investigator-initiated trial of FRα-CoStAR TIL in non-small cell lung cancer.
- Company is exploring in-licensing or acquiring novel therapeutic candidates for unmet needs.

## SEC filing metadata
- accession: 0001789769-24-000057
- form_type: 8-K
- ticker: TIL
- cik: 0001789769
- company_name: Instil Bio, Inc.
- filed_at: 2024-05-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1789769/000178976924000057/0001789769-24-000057-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1789769/000178976924000057/til-20240510.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001789769-24-000057
- JSON: https://secwatch.observer/filing/0001789769-24-000057.json
- Plain text: https://secwatch.observer/filing/0001789769-24-000057.txt

## Key facts
- Earnings Releases
  Instil Bio, Inc. reported the quarter ended March 31, 2024 results: EPS Net loss per share, basic and diluted were $3.74.
  - Period: the quarter ended March 31, 2024
  - EPS: Net loss per share, basic and diluted were $3.74
  - Result: reported results
  source text: On May 10, 2024 , Instil Bio, Inc. (the “Company”) provided a corporate update and announced its financial results for the quarter ended March 31, 2024 in the press release attached hereto as Exhibit 99.1, which is incorporated herein by reference.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1789769/000178976924000057/0001789769-24-000057-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.